Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135].

Trial Profile

Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135].

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Contusugene ladenovec (Primary) ; Contusugene ladenovec (Primary)
  • Indications Head and neck cancer; Mouth disorders; Pharyngeal disorders
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 22 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov (NCT00064103).
    • 22 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov (NCT00064103).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top